In a large, “real-world” study (N = 7069) across many lines of treatment (first-, second-, or third-line of therapy), KRAS G12C/STK11 co-mutations were not shown to impact the median OS as compared to KRAS WT or all NSCLC patients (including all KRAS mutations beyond G12C): 9 vs. 8.6 months, vs. 8.9 months in the patients [37]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.